Stockscreener 앱 받기
125.84
2.26%
2.78
시간 외 거래:
125.84
Repligen Corp 주식(RGEN)의 최신 뉴스
Repligen Corporation $RGEN Shares Sold by TD Asset Management Inc - MarketBeat
NZS Capital LLC Has $26.30 Million Stake in Repligen Corporation $RGEN - MarketBeat
Repligen (RGEN) COO uses 3,911 shares to cover tax withholding - Stock Titan
Repligen (RGEN) CEO reports tax-withholding share dispositions in Form 4 - Stock Titan
Repligen (RGEN) director uses 9,897 shares to cover RSU taxes - Stock Titan
Repligen (RGEN) CFO stock withheld to cover RSU tax obligations - Stock Titan
Repligen (RGEN) SVP uses company shares to cover RSU taxes - Stock Titan
Repligen (RGEN) CPO has shares withheld to cover RSU tax bill - Stock Titan
Repligen Corporation (RGEN) Investor Outlook: Exploring a 44.7% Potential Upside in the Bioprocessing Sector - DirectorsTalk Interviews
Repligen Corporation $RGEN Position Boosted by Royce & Associates LP - MarketBeat
3 Reasons to Avoid RGEN and 1 Stock to Buy Instead - Finviz
Artisan Partners Limited Partnership Has $28.44 Million Stock Holdings in Repligen Corporation $RGEN - MarketBeat
Primecap Management Co. CA Has $24.98 Million Stock Position in Repligen Corporation $RGEN - MarketBeat
Repligen (NASDAQ:RGEN) Downgraded to Hold Rating by Wall Street Zen - MarketBeat
Privia Health, Repligen, and RadNet Shares Plummet, What You Need To Know - Yahoo Finance
Repligen Corp (RGEN) Shares Down 3.09% on Feb 27 - GuruFocus
Oversold Conditions For Repligen (RGEN) - Nasdaq
Decoding Repligen Corp (RGEN): A Strategic SWOT Insight - GuruFocus
Repligen (NASDAQ: RGEN) maps 2025 bioprocessing market, debt and control risks - Stock Titan
A Glimpse Into The Expert Outlook On Repligen Through 6 Analysts - Benzinga
Repligen Offers Differentiated Solutions as a Leading Bioprocessing Supplier - Morningstar
Barclays Has Lowered Expectations for Repligen (NASDAQ:RGEN) Stock Price - MarketBeat
Barclays Adjusts Repligen (RGEN) Target Price Amid Overweight Ra - GuruFocus
Wells Fargo Lowers Price Target for RGEN, Maintains Overweight R - GuruFocus
Repligen's Q4 Earnings Beat Estimates, Revenues Surge Y/Y - Finviz
Repligen (NASDAQ:RGEN) Price Target Lowered to $180.00 at Wells Fargo & Company - MarketBeat
Evercore ISI Group Lowers Price Target for Repligen (RGEN) to $1 - GuruFocus
KeyBanc reiterates Repligen stock rating on product momentum - Investing.com
How The Repligen (RGEN) Narrative Is Shifting With New Targets M&A Plans And Products - Yahoo Finance
Repligen (RGEN) Return To Profitability Tests Bullish Growth Narrative In Q4 2025 Results - simplywall.st
Repligen Corporation Q4 2025 Earnings Call Summary - Yahoo Finance
Repligen Corp (RGEN) Q4 2025 Earnings Call Highlights: Strong Or - GuruFocus
Repligen earnings beat by $0.05, revenue topped estimates By Investing.com - Investing.com South Africa
Repligen Q4 Earnings Call Highlights - Yahoo Finance
Repligen Q4 2025 Earnings Beat Estimates, Provides 2026 OutlookNews and Statistics - IndexBox
Earnings call transcript: Repligen Q4 2025 earnings surpass expectations - Investing.com
Earnings call transcript: Repligen Q4 2025 earnings surpass expectations By Investing.com - Investing.com Canada
Repligen Corp. Experiences Revision in Stock Evaluation Amid Market Challenges - Markets Mojo
Repligen (RGEN) Tops Q4 Earnings and Revenue Estimates - Yahoo Finance
Repligen (NASDAQ:RGEN) Updates FY 2026 Earnings Guidance - MarketBeat
Repligen (RGEN) Beats Q4 Revenue Expectations with Strong Organi - GuruFocus
Repligen beats Q4 estimates but guides below consensus for 2026 By Investing.com - Investing.com South Africa
Repligen Corp (NASDAQ:RGEN) Stock Falls Despite Q4 Earnings Beat as 2026 Guidance Disappoints - ChartMill
Repligen earnings beat by $0.05, revenue topped estimates - Investing.com
Repligen (NASDAQ:RGEN) Exceeds Q4 CY2025 Expectations - Finviz
Repligen: Fourth Quarter Earnings Overview - Bitget
REPLIGEN ($RGEN) Releases Q4 2025 Earnings - Quiver Quantitative
Repligen beats Q4 estimates but guides below consensus for 2026 - Investing.com
Repligen: Q4 Earnings Snapshot - marketscreener.com
Repligen Q4 Earnings Report: What Investors Need to Know - Benzinga
Repligen Corporation Reports Q4 and Full Year 2025 Financial Results - TradingView
Earnings Flash (RGEN) Repligen Corporation Reports Q4 Revenue $197.9M, vs. FactSet Est of $192.9M - marketscreener.com
From loss to profit: bioprocessing firm Repligen targets 10–14% 2026 growth - Stock Titan
Repligen (RGEN) Q4 2025 Earnings Call Transcript - The Globe and Mail
Repligen Earnings Preview - Benzinga
Repligen earnings in focus as bioprocessing recovery takes hold By Investing.com - Investing.com South Africa
Repligen earnings in focus as bioprocessing recovery takes hold - Investing.com
Repligen (RGEN) To Report Earnings Tomorrow: Here Is What To Expect - Finviz
Repligen (FRA:RGN) PB Ratio : 3.67 (As of Feb. 20, 2026) - GuruFocus
CenterBook Partners LP Takes $2.36 Million Position in Repligen Corporation $RGEN - MarketBeat
Repligen Corp. (RGEN) Rose as Industrial Destocking Decreased and Order Patterns Stabilized - Insider Monkey
2 of Wall Street's Favorite Stocks Worth Investigating and 1 We Avoid - Finviz
Repligen Corporation (NASDAQ:RGEN) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
RGEN Technical Analysis & ETF Price Forecast - Intellectia AI
Repligen (NASDAQ: RGEN) Eddleman trusts report passive stake under 5% - Stock Titan
Impax Asset Management Group plc Reduces Position in Repligen Corporation $RGEN - MarketBeat
0.58%
0.28%
자본화:
|
볼륨(24시간):